We were excited to attend the American College of Toxicology (ACT) 2024 annual meeting in Austin, Texas!
ACT is a global community of professional scientists representing the pharmaceutical and biotech industries, regulatory agencies, contract research organizations, academia, and consulting firms. The 45th Annual Meeting included a wide-ranging scientific program and educational courses, with distinguished plenary speakers, the popular Poster Session, an Awards Ceremony, and multiple professional networking events.
Lhasa held an industry hosted session discussing:
Setting limits for nitrosamines and other impurity classes using in silico approaches, including read-across.
Tuesday 19th November, 12:00 – 12:55
We evaluated the toxicological risks posed by nitrosamines and other impurity classes. We demonstrated how the Lhasa carcinogenic potency categorisation approach (CPCA) tool can support your impurity assessment, and how it can determine compound-relevant limits for these impurity types using a transparent in silico read-across workflow.
This session was hosted by Director of Science at Lhasa, Dr Adrian Fowkes, and Senior Application Scientist, Dr Charlie Modlin.